Avvio Medical
San Francisco, US · Delaware corporation · 2 known investors
Find your way into Avvio Medical
279 people in our graph share verified history with the Avvio Medical team — schools, employers, funds. One of them is your warm intro.
David Phuunlockedknows Alice Luong · together at University of California, Davis (overlapped)
×4knows the team · via UC San Diego
knows the team · via The University of Chicago Booth School of Business
×4knows the team · via University of California, Davis
knows the team · via Texas A&M University
knows the team · via Teleflex
Avvio AMEA develops kidney stone treatment technology for urological care, targeting patients and healthcare providers across Asia, the Middle East, and Africa. It is the regional arm of Avvio Medical, whose investigational medical device has not yet received regulatory clearance.
Founders & leadership
MS
Marshall StollerFounder
RG
Robert Grubbs, PhD (deceased)Founder
CM
Claire Mills, RDMS, RVTFounder
PM
Paul MolloyinCEO and DirectorPaul Molloy is a CEO and board director with experience leading public and private medical device companies through growth, operations, and capital markets activities. He has overseen multiple successful exits including mergers, acquisitions, corporate spin-offs, and an IPO.
BZ
Ben ZadikExecutive
GJ
Greg JohnstoneCFO
SL
Susie LaheyVice President of Corporate Administration
LM
Louis MarcouxinVice President of Regulatory, Quality and Clinical AffairsLouis Marcoux is Vice President of Regulatory, Quality and Clinical Affairs at Avvio Medical, a developer of kidney stone treatment technology. He has experience in regulatory strategy, FDA and EU MDR compliance, and global medical device registrations.
AL
Alice LuonginDirector of Technical Operations and Head of Chemistry (PhD)Alice Luong holds a PhD and serves as Director of Technical Operations and Head of Chemistry at Avvio Medical, where she leads manufacturing process development and regulatory compliance for the company's investigational kidney stone treatment device.
AS
Amy SasserinDirector of Clinical AffairsShe co-founded a clinical site management organization in 1999 and has spent over two decades managing clinical trials and research operations across both site and industry roles.
LC
Liu ChangNamed on SEC filing
JG
John GarciaNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$38M disclosed across 3 rounds · 2020–2024
▶$7.1MraisedNov 2024 · 25 investors · Other Health CareRule 506(b)
▶$7.1MraisedNov 2024 · 25 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Paul MolloyExecutive Officer, Director
- Theresa YuDirector
- Dongxue WangDirector
- Quinten StevensDirector
- Barry TemplinDirector
- Gregory JohnstoneExecutive Officer
- Thomas KennyDirector
- Alex AndrianopoulosDirector
- Biao HeDirector
- Offering amount
- $15M
- Amount sold
- $7.1M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.7MraisedJul 2022 · 5 investors · Other Health CareRule 506(b)
▶$5.7MraisedJul 2022 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Thomas KennyExecutive Officer, Director
- Ben ZadikExecutive Officer
- Quinten StevensDirector
- Alex AndrianopoulosDirector
- Gordon SaulDirector
- Changan LiDirector
- Biao HeDirector
- Theresa YuDirector
- John GarciaDirector
- Offering amount
- $16M
- Amount sold
- $5.7M
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25.2MraisedFeb 2021 · 67 investors · Other Health CareRule 506(b)
▶$25.2MraisedFeb 2021 · 67 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Liu ChangDirector
- Biao HeDirector
- Thomas KennyExecutive Officer, Director
- John GarciaDirector
- Ben ZadikExecutive Officer
- Alex AndrianopoulosDirector
- Gordon SaulDirector
- Offering amount
- $34.6M
- Amount sold
- $25.2M
- Sales commissions
- $398.6K
- Placement agents
- SV 1898 Group, Inc.
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Boston Scientific6 shared keywordsBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Genhealth4 shared keywordsGenHealth provides AI-based revenue cycle management and administrative automation for healthcare providers and DME teams, handling intake, eligibility, claims, prior authorization, denials, and appeals. Its browser agent extracts data from faxes and documents and routes it into EMR and billing systems, targeting independent physician groups and providers.
Companies competing with Avvio Medical for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Avvio Medical do?
- Avvio AMEA develops kidney stone treatment technology for urological care, targeting patients and healthcare providers across Asia, the Middle East, and Africa. It is the regional arm of Avvio Medical, whose investigational medical device has not yet received regulatory clearance.
- Who founded Avvio Medical?
- Avvio Medical was founded by Marshall Stoller, Robert Grubbs, PhD (deceased), Claire Mills, RDMS, RVT.
- Who are Avvio Medical's investors?
- Avvio Medical's investors include Global Bridge Capital, Kairos Venture Investments, Llc.
- How much funding has Avvio Medical raised?
- Avvio Medical has disclosed $38M raised across 3 rounds.
- Where is Avvio Medical headquartered?
- Avvio Medical is headquartered in San Francisco, US.